Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market scope and definition
1.3 Base estimates and calculations
1.4 Forecast calculations
1.5 Data sources
1.5.1 Primary
1.5.2 Secondary
1.5.2.1 Paid sources
1.5.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Veterinary antimicrobial susceptibility testing market, 2018 - 2032
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Animal trends
2.1.4 End User trends
2.1.5 Regional trends
Chapter 3 Veterinary Antimicrobial Susceptibility Testing Market Industry Insights
3.1 Industry ecosystem analysis
3.2 Vendor matrix
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing demands for animal-derived diet items
3.3.1.2 Increasing government initiatives
3.3.1.3 Rising demand for livestock products
3.3.2 Industry pitfalls & challenges
3.3.2.1 Stringent regulatory policies
3.3.2.2 High cost of automated veterinary antimicrobial susceptibility testing systems
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By animal
3.4.3 By end user
3.4.4 By region
3.5 Regulatory scenario
3.5.1 U.S.
3.5.2 Canada
3.5.3 Europe
3.6 Porter's analysis
3.6.1 Industry rivalry
3.6.2 Buyer power
3.6.3 Supplier power
3.6.4 Threat of substitute
3.6.5 Threat of new entrants
3.7 PESTEL analysis
3.7.1 Political
3.7.2 Economical
3.7.3 Social
3.7.4 Technological
3.7.5 Environmental
3.7.6 Legal
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Product portfolio matrix
4.2.1 BioMérieux SA
4.2.2 Becton, Dickinson and Company
4.2.3 Synbiosis
4.2.4 Thermo Fisher Scientific
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix
Chapter 5 Veterinary Antimicrobial Susceptibility Testing Market, By Product Type
5.1 Key segment trends
5.2 Disks and plates
5.2.1 Market size, by region, 2018 - 2032 (USD Million)
5.3 Culture media
5.3.1 Market size, by region, 2018 - 2032 (USD Million)
5.4 Accessories and consumables
5.4.1 Market size, by region, 2018 - 2032 (USD Million)
5.5 Automated AST instruments
5.5.1 Market size, by region, 2018 - 2032 (USD Million)
5.6 Urinalysis
5.6.1 Market size, by region, 2018 - 2032 (USD Million)
5.7 Other products
5.7.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 6 Veterinary Antimicrobial Susceptibility Testing Market, By Animal Type
6.1 Key segment trends
6.2 Companion animal
6.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.2.2 Dogs
6.2.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.2.3 Cats
6.2.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.2.4 Horses
6.2.4.1 Market size, by region, 2018 - 2032 (USD Million)
6.2.5 Other companion animals
6.2.5.1 Market size, by region, 2018 - 2032 (USD Million)
6.3 Livestock
6.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.3.2 Cattle
6.3.2.1 Market size, by region, 2018 - 2032 (USD Million)
6.3.3 Swine
6.3.3.1 Market size, by region, 2018 - 2032 (USD Million)
6.3.4 Poultry
6.3.4.1 Market size, by region, 2018 - 2032 (USD Million)
6.3.5 Sheep & goats
6.3.5.1 Market size, by region, 2018 - 2032 (USD Million)
6.3.6 Other livestock
6.3.6.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 7 Veterinary Antimicrobial Susceptibility Testing Market, By End User
7.1 Key segment trends
7.2 Veterinary reference laboratories
7.2.1 Market size, by region, 2018 - 2032 (USD Million)
7.3 Veterinary research institutes and universities
7.3.1 Market size, by region, 2018 - 2032 (USD Million)
7.4 Others
7.4.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 8 Veterinary Antimicrobial Susceptibility Testing Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Switzerland
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 BioMérieux SA
9.1.1 Business overview
9.1.2 Financial data
9.1.3 Product landscape
9.1.4 Strategic outlook
9.1.5 SWOT analysis
9.2 Becton, Dickinson and Company
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Product landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Synbiosis
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Product landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 Thermo Fisher Scientific
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Product landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 Bruker Corporation
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Product landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 Danaher Corporation
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Product landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 Condalab
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Product landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Bioguard Corporation
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Product landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 Liofilchem S.r.l.
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Product landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 HiMedia Laboratories
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Product landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Bio-Rad Laboratories
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Product landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
9.12 Neogen Corporation
9.12.1 Business overview
9.12.2 Financial data
9.12.3 Product landscape
9.12.4 Strategic outlook
9.12.5 SWOT analysis
